In its time as an independent company, Hospira has become the world leader in specialty generic injectable pharmaceuticals, offering one of the broadest portfolios of generic acute-care and oncology injectables. Additionally, Hospira is a top provider of integrated infusion therapy and medication management solutions. Highlights of the company's rich history include:

2010

• Acquire Orchid’s generic injectable pharmaceuticals business, strengthening the company's position in beta-lactam antibiotics
• Help lead successful efforts toward the creation of a biosimilars pathway in the United States; pathway included in historic healthcare reform legislation
• Standardize intravenous (I.V.) administration sets portfolio to a more environmentally friendly, non-DEHP (non-di(2-ethylhexyl) phthalate) plasticizer
• Launch Hospira’s second biosimilar, Nivestim™ (filgrastim) in Europe
• Receive approval for meropenem, a beta-lactam antibiotic
• Acquire Javelin Pharmaceuticals company, broadening Hospira’s pain management portfolio
• Receive approval of Nivestim in Australia
• Sign strategic agreement with Smiths Medical, expanding Hospira's infusion pump offerings to include syringe pump
• Launch piperacillin and tazobactam antibiotic
• Launch gemcitabine hydrochloride oncology drug
• Drive annualized ongoing savings target of $110 million to $140 million from Project Fuel optimization efforts
• Double company's market capitalization to approximately $9 billion, up from $4.2 billion in 2004
• Provide support to Hospira's global communities through monetary and product donations totaling more than $65 million since Hospira's launch in 2004
• Achieve annual sales of $3.9 billion

2009

• Achieve the industry’s first-ever successful integration of infusion pumps with the electronic health record
• Acquire the biosimilar filgrastim and its related manufacturing facility
• Forge agreement with Celltrion to develop and market biosimilar drugs, significantly expanding Hospira’s biosimilars pipeline to be one of the largest in the industry
• Acquire TheraDoc™ clinical informatics company and clinical surveillance technology
• Launch Project Fuel optimization effort to simplify the business, drive continuous improvement and bolster operational excellence
• Achieve annual sales of $3.9 billion

2008

• Launch irinotecan hydrochloride oncology drug
• Introduce Retacrit™ (epoetin zeta), Hospira’s first biosimilar in Europe
• Acquire VeriScan Rx™ medication administration system technology
• Acquire EndoTool™ glucose management system software
• Achieve annual sales of $3.6 billion

2007

• Acquire Mayne Pharma Limited, doubling Hospira’s international sales to 30 percent of total sales and positioning Hospira as the worldwide leader in generic injectable pharmaceuticals
• Launch iSecure™, Hospira's proprietary prefilled disposable syringe
• Achieve annual sales of $3.44 billion

2006

• Introduce VisIV™ next-generation container, the first significantly advanced I.V. bag in 30 years
• Acquire BresaGen biotechnology company
• Launch Symbiq™ infusion system, a medically and technologically advanced medication management system
• Sign strategic agreements with STADA and BIOCEUTICALS for a biosimilar product
• Launch of ondansetron antiemetic (prevents nausea and vomiting)
• Achieve annual sales of $2.69 billion

2005

• Introduce wireless Hospira MedNet™ drug library safety software
• Achieve annual sales of $2.63 billion

2004

• Launch Hospira, Inc., a spin-off from Abbott Laboratories, guided by Christopher B. Begley as founding CEO and publicly traded on the New York Stock Exchange (NYSE) under ticker symbol ‘HSP’
• Establish Hospira Foundation, the philanthropic arm of Hospira, Inc.
• Launch fluconazole antifungal treatment
• Achieve annual sales of $2.6 billion

Previously, as the hospital products business of Abbott Laboratories:

2000s

• Introduce Hospira MedNet drug library safety software
• Complete industry-leading patient safety effort to affix unit-of-use bar codes to all of our more than 1,000 hospital injectable pharmaceuticals and I.V. solutions

1990s

• Expand generic acute-care injectables portfolio, helping to reduce the high cost of proprietary pharmaceuticals
• Introduce premixed solutions
• Introduce prefilled syringes to help reduce the potential for medication errors and increase convenience
• Introduce needleless products to improve healthcare worker safety
• Launch proprietary sedation agent Precedex™

1980s

• Discover and launch of the world's first patient-controlled analgesia (PCA) device
• Acquire high-tech critical care monitoring systems
• Introduce ADD-Vantage™ drug delivery system, helping decrease pharmacy preparation time and delivery time to patient

1970s

• Discover and launch the company's first electronic drug delivery pump
• Introduce the company's first flexible I.V. container, decreasing the use of glass in the hospital

1940s-1950s

• Introduce the first fully disposable I.V. administration set
• Introduce new protein solution for I.V. feeding